In the upper part of the CAC 40 table, Sanofi stock rebounds by 1.5%
The pharmaceutical company is recovering mid-session, in a CAC 40 that is progressing slightly. This upturn contrasts with a year marked by a clear decline, and the stock remains trapped between two technical levels monitored for several weeks.
A rebound that brings the stock back into contact with its 20-day average
The Sanofi stock gains 1.54% to €72.70, against a gain of 0.27% for the CAC 40 and 0.30% for the SBF 120. This increase places it among the strongest gains in the Paris index, behind Pernod Ricard (+2.79%) and Veolia (+2.43%). The group continues the recovery begun in early October, after a low since 2018 reached on October 2nd. Over seven days, the gain reaches 3.87%, while the decline over one year remains at 12.77%.
The price is now in contact with the 20-day MA (€72.50) and remains below the 50-day MA at €74.70, a gap of 2.68%. The RSI at 44 is neutral, and the MACD, whose histogram is slightly returning to positive territory, signals a clear slowdown in selling pressure. Support at €69.99 remains the lower reference, resistance at €77.16 the upper reference.
A valuation of 8.5 times earnings and a share buyback in the background
Based on expected earnings per share, the stock trades at approximately 8.5 times current year earnings, according to the consensus of surveyed analysts, and 8.0 times next year's earnings, with expected EPS growth of 5.2%. The group has also repurchased approximately €1.7 billion of its own shares over twelve months, or 1.9% of its capitalization, according to its latest statement of April 28, 2026. On the corporate front, the expansion of the collaboration with Regeneron to four new antibodies, announced on October 1st, and the planned entry into Cheplapharm's capital at 26.4% are the two most recent corporate developments. Tuesday's session also sees Eurofins Scientific gain 0.88%, while Nanobiotix declines by 0.86%, with a decline of 33.67% over one month.
